NASDAQ:XAIR 14 January 2026

March 21, 2026, 6:53 AM EDT. Shares of multi-cancer early detection company Grail jumped up to 12.4% this week following a Wall Street analyst's rating upgrade from "hold" to "buy." The new price target, however, was lowered to $65, still offering a 39% premium over the last close. This comes despite the company missing its primary endpoint in a key trial measuring stage III-IV cancer detection reductions with its Galleri test. The trial did show promising increases in early-stage cancer detection and reduced late-stage cases, which investors hope will be bolstered by upcoming follow-up data. Analyst TD Cowen cited potential for FDA approval and insurance coverage as reasons for optimism in a volatile healthcare stock environment.